Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Monte Rosa Therapeutics Inc’s stock clocked out at $16.45, up 0.86% from its previous closing price of $16.31. In other words, the price has increased by $0.86 from its previous closing price. On the day, 0.66 million shares were traded. GLUE stock price reached its highest trading level at $17.17 during the session, while it also had its lowest trading level at $16.17.
Ratios:
To gain a deeper understanding of GLUE’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.74 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.39. For the most recent quarter (mrq), Quick Ratio is recorded 6.54 and its Current Ratio is at 6.54. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $11 from $14 previously.
On February 15, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $11.
Wells Fargo Upgraded its Equal Weight to Overweight on January 03, 2023, while the target price for the stock was maintained at $18.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 03 ’25 when Dunn Edmund sold 2,062 shares for $4.45 per share. The transaction valued at 9,174 led to the insider holds 23,732 shares of the business.
Leo Chandra P. bought 10,000 shares of GLUE for $58,383 on Mar 24 ’25. The Director now owns 10,000 shares after completing the transaction at $5.84 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLUE now has a Market Capitalization of 1071187200 and an Enterprise Value of 720097152. As of this moment, Monte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 53.86. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.90 while its Price-to-Book (P/B) ratio in mrq is 4.13. Its current Enterprise Value per Revenue stands at 3.967 whereas that against EBITDA is 42.761.
Stock Price History:
The Beta on a monthly basis for GLUE is 1.60, which has changed by 1.1264668 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, GLUE has reached a high of $18.15, while it has fallen to a 52-week low of $3.50. The 50-Day Moving Average of the stock is 25.11%, while the 200-Day Moving Average is calculated to be 131.35%.
Shares Statistics:
It appears that GLUE traded 1.57M shares on average per day over the past three months and 750600 shares per day over the past ten days. A total of 61.79M shares are outstanding, with a floating share count of 40.96M. Insiders hold about 37.10% of the company’s shares, while institutions hold 70.72% stake in the company. Shares short for GLUE as of 1764288000 were 7006369 with a Short Ratio of 4.46, compared to 1761868800 on 7988754. Therefore, it implies a Short% of Shares Outstanding of 7006369 and a Short% of Float of 14.02.
Earnings Estimates
The market rating of Monte Rosa Therapeutics Inc (GLUE) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.37 and low estimates of -$0.53.
Analysts are recommending an EPS of between $0.04 and -$0.44 for the fiscal current year, implying an average EPS of -$0.2. EPS for the following year is -$1.37, with 7.0 analysts recommending between $0.25 and -$2.03.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for GLUE’s current fiscal year. The highest revenue estimate was $160.9M, while the lowest revenue estimate was $121M, resulting in an average revenue estimate of $136.47M. In the same quarter a year ago, actual revenue was $75.62M
